New cyanoanthranylamide derivatives, useful for treating e.g. psoriasis and Kaposi's sarcoma, are inhibitors of angiogenesis, acting selectively on specific tyrosine kinases

摘要

Cyanoanthranylamide derivatives (I) are new. Cyanoanthranylamide derivatives of formula (I) and their salts and isomers are new. A = NR7; W = O, S, H2 or NR8; Z = bond, NR10, =N-, 1-12C optionally branched alkyl or the group -(CRaRb)m-(CRcRd)n-(CReRf)o-; m, n, o = 0-3; Ra-Rf = H, F, 1-4C alkyl or N(R1)2; or Ra and/or Rb with Rc and/or Rd or Rc with Re and/or Rf = bond; or 2 Ra-Rf = bridge of up to 3 C to R1 or R7; R1 = 1-12C alkyl or 2-12C alkenyl (optionally substituted by 1 or more halo, OH, 1-6C alkoxy, aralkoxy, 1-6C alkyl and/or NR12R13), 3-10C cycloalkyl or cycloalkenyl (optionally substituted as above but not by aralkoxy) or (hetero)aryl (optionally substituted by one or more halo, OH, 1-6C alkoxy, aralkoxy, 1-6C (halo)alkyl, OR14 or R14); Y1-Y5 = N or CY6; Y6 = CN, halo, 1-6C alkyl or alkoxy or hydroxy; D-G = N or CRx; Rx = H, halo, or 1-6C alkoxy, alkyl or carboxyalkyl (all optionally substituted by one or more halo); R7 = H or 1-6C alkyl or with Ra-Rf forms a bridge of up to 3 ring members; R8 -R11 = H or 1-6C alkyl; R12, R13 = H, 1-6C alkyl or a ring that may contain another heteroatom; R14 = 1-15C alkyl-R15, (alkyl optionally interrupted by 1 or more O, or (CH2CH2O)u(CH2)v-R15; R15 = (hetero)aryl, 1-6C alkyl, aralkyl, cyanomethyl or NR16R17; R16, R17 = H, 1-6C alkyl or acyl, or a ring that may include a further heteroatom; and u, v = 0-5; provided that the ring containing Y6 includes at least one nitrogen and carries at least one cyano.